Compare Abeona Therapeutics Inc (ABEO) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Msci Inc — how do they compare? Abeona Therapeutics Inc trades at $7.39 (market cap $421.19M), while Msci Inc trades at $560.16 (market cap $40.84B). The key difference: Msci Inc is far larger — about 97× Abeona Therapeutics Inc's market cap, and Msci Inc pays a 1.46% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MSCI | |
|---|---|---|
Market Cap | $421.19M | $40.84B |
Sector | Health | Financials |
52-Week High | $7.45 | $643.83 |
52-Week Low | $4.17 | $511.84 |
Enterprise Value | $276.10M | $47.00B |
Dividend Yield | — | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
MSCI trades at $562.00, down 0.19% in the last 24 hours, with a bearish technical signal from moving averages but oversold RSI hints at potential rebound. The company reported Q2 2026 EPS of $4.94, slightly missing the $4.99 estimate, yet revenue growth remains robust, with 2025 revenue at $3.13 billion and net income margin of 40.73%. Recent acquisitions like First Street and partnerships with UBS aim to expand its private markets analytics platform, supporting long-term growth.
Outlook is positive with a consensus price target of $728.14, implying 30% upside, driven by strong recurring revenue and high client retention. Risks include elevated debt levels of $4.51 billion and competitive pressures in financial data services. Analysts maintain 73% buy ratings, citing undervaluation relative to growth prospects, but investors should monitor execution on integration of recent acquisitions and interest rate impacts on financing costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
